Prognostic implications of HER2 gain in patients with HR+/ HER2-breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)

被引：0
|
作者：
Ferraro, E. [1 ]
Minmin, S. Chew [1 ]
Nemirovsky, D. [2 ]
Chen, Y. [2 ]
Barrio, A. V. [3 ]
Modi, S. [1 ]
Seidman, A. [1 ]
Wen, H. [4 ]
Brogi, E. [4 ]
Robson, M. [5 ]
Dang, C. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Breast Med Serv, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Biostat, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Breast Surg, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA
[5] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[6] MSKCC Mem Sloan Kettering Westchester, Dept Breast Oncol, West Harrison, IN USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.488
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
291P
引用
收藏
页码：S301 / S301
页数：1
相关论文
共 50 条
  • [1] Gain of HER2 Amplification in Patients with HR+/HER2-and Triple Negative Early Breast Cancer Treated with Neoadjuvant Chemotherapy
    Ferraro, Emanuela
    Minmin, Sonya Chew
    Safonov, Anton
    Barrio, Andrea V.
    Modi, Shanu
    Seidman, Andrew D.
    Wen, Hanna Y.
    Brogi, Edi
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Prognostic implications of HER2 change after neoadjuvant chemotherapy in HER2-positive breast cancer patients
    Sato, A.
    Maeda, Y.
    Matsumoto, A.
    Ikeda, T.
    Jinno, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1409 - S1409
  • [3] IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2-breast cancer patients after neoadjuvant chemotherapy
    Huang, Zhenhua
    Liu, Yao
    Li, Shunyin
    Li, Yudong
    Wu, Zongqi
    He, Haiyan
    Yang, Yaping
    Jin, Liang
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 307 - 319
  • [4] Conventional Tools for Predicting Satisfactory Response to Neoadjuvant Chemotherapy in HR+/HER2-Breast Cancer Patients
    Oprea, Adela Luciana
    Gulluoglu, Bahadir
    Aytin, Yusuf Emre
    Eren, Ozgur Can
    Aral, Canan
    Szekely, Tiberiu-Bogdan
    Tastekin, Ebru
    Kaya, Handan
    Bademler, Sueleyman
    Karanlik, Hasan
    Sezer, Atakan
    Ugurlu, Mustafa Umit
    Turdean, Sabin Gligore
    Georgescu, Rares
    Marginean, Claudiu
    BREAST CARE, 2023, 18 (05) : 344 - 353
  • [5] The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
    Sarina, Piha-Paul
    Xu, Binghe
    Fan, Ying
    Yuan, Yuan
    Lavasani, Sayeh
    Mortimer, Joanne
    Goel, Sanjay
    Tsimberidou, Apostolia
    Ibrahim, Nuhad
    Abouharb, Sausan
    Barcenas, Carlos
    Lheme, Adaeze
    Karp, Daniel
    Ahnert, Jordi Rodon
    Dumbrava, Ecaterina
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Xu, Ruolan
    Ni, Shumao
    Wu, Frank
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
    Kang, Sora
    Lee, So Heun
    Lee, Hee Jin
    Jeong, Hyehyun
    Jeong, Jae Ho
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Gong, Gyungyub
    Kim, Hak Hee
    Lee, Saebyeol
    Lee, Jongwon
    Kim, Sung-Bae
    EUROPEAN JOURNAL OF CANCER, 2023, 191
  • [7] Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
    Kang, S.
    Lee, S. H.
    Lee, H. J.
    Jeong, H.
    Jeong, J-H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Kim, H. H.
    Lee, S.
    Lee, J.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2023, 34 : S305 - S305
  • [8] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [9] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [10] SG Improves OS in HR+/HER2-Breast Cancer
    Poh, Alissa
    CANCER DISCOVERY, 2022, 12 (12) : 2714 - 2715
12345